Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation (Englisch)
- Neue Suche nach: Erdem-Eraslan, L.
- Neue Suche nach: Gao, Y.
- Neue Suche nach: Kloosterhof, N.K.
- Neue Suche nach: Atlasi, Y.
- Neue Suche nach: Demmers, J.
- Neue Suche nach: Sacchetti, A.
- Neue Suche nach: Kros, J.M.
- Neue Suche nach: Sillevis Smitt, P.
- Neue Suche nach: Aerts, J.
- Neue Suche nach: Erdem-Eraslan, L.
- Neue Suche nach: Gao, Y.
- Neue Suche nach: Kloosterhof, N.K.
- Neue Suche nach: Atlasi, Y.
- Neue Suche nach: Demmers, J.
- Neue Suche nach: Sacchetti, A.
- Neue Suche nach: Kros, J.M.
- Neue Suche nach: Sillevis Smitt, P.
- Neue Suche nach: Aerts, J.
In:
EUROPEAN JOURNAL OF CANCER -A-
;
51
, 7
;
893-903
;
2015
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation
-
Beteiligte:Erdem-Eraslan, L. ( Autor:in ) / Gao, Y. ( Autor:in ) / Kloosterhof, N.K. ( Autor:in ) / Atlasi, Y. ( Autor:in ) / Demmers, J. ( Autor:in ) / Sacchetti, A. ( Autor:in ) / Kros, J.M. ( Autor:in ) / Sillevis Smitt, P. ( Autor:in ) / Aerts, J. ( Autor:in )
-
Erschienen in:EUROPEAN JOURNAL OF CANCER -A- ; 51, 7 ; 893-903
-
Verlag:
- Neue Suche nach: Elsevier Science B.V., Amsterdam
-
Erscheinungsdatum:01.01.2015
-
Format / Umfang:11 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 616.994
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 616.994 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 51, Ausgabe 7
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 791
-
Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: Evaluation of concordance between genomic and transcriptional profilesVignot, S. / Lefebvre, C. / Frampton, G.M. / Meurice, G. / Yelensky, R. / Palmer, G. / Capron, F. / Lazar, V. / Hannoun, L. et al. | 2015
- 800
-
Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysisPetrelli, F. / Pietrantonio, F. / Cremolini, C. / Di Bartolomeo, M. / Coinu, A. / Lonati, V. / de Braud, F. / Barni, S. et al. | 2015
- 808
-
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trialNishikawa, K. / Fujitani, K. / Inagaki, H. / Akamaru, Y. / Tokunaga, S. / Takagi, M. / Tamura, S. / Sugimoto, N. / Shigematsu, T. et al. | 2015
- 817
-
Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up studyGarcia-Albeniz, X. / Chan, J.M. / Paciorek, A. / Logan, R.W. / Kenfield, S.A. / Cooperberg, M.R. / Carroll, P.R. / Hernan, M. et al. | 2015
- 825
-
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patientsSehouli, J. / Fotopoulou, C. / Erol, E. / Richter, R. / Reuss, A. / Mahner, S. / Lauraine, E.P. / Kristensen, G. / Herrstedt, J. et al. | 2015
- 833
-
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaSchadendorf, D. / Amonkar, M.M. / Stroyakovskiy, D. / Levchenko, E. / Gogas, H. / de Braud, F. / Grob, J.J. / Bondarenko, I. / Garbe, C. et al. | 2015
- 841
-
RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 statusSonnemann, J. / Grauel, D. / Blumel, L. / Hentschel, J. / Marx, C. / Blumrich, A. / Focke, K. / Becker, S. / Wittig, S. et al. | 2015
- 852
-
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinibLee, C.K. / Goldstein, D. / Gibbs, E. / Joensuu, H. / Zalcberg, J. / Verweij, J. / Casali, P.G. / Maki, R.G. / Cioffi, A. et al. | 2015
- 861
-
443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011Brecht, I.B. / Garbe, C. / Gefeller, O. / Pfahlberg, A. / Bauer, J. / Eigentler, T.K. / Offenmueller, S. / Schneider, D.T. / Leiter, U. et al. | 2015
- 869
-
The forthcoming inexorable decline of cutaneous melanoma mortality in light-skinned populationsAutier, P. / Koechlin, A. / Boniol, M. et al. | 2015
- 879
-
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesWinterhoff, B. / Freyer, L. / Hammond, E. / Giri, S. / Mondal, S. / Roy, D. / Teoman, A. / Mullany, S.A. / Hoffmann, R. et al. | 2015
- 893
-
Mutation specific functions of EGFR result in a mutation-specific downstream pathway activationErdem-Eraslan, L. / Gao, Y. / Kloosterhof, N.K. / Atlasi, Y. / Demmers, J. / Sacchetti, A. / Kros, J.M. / Sillevis Smitt, P. / Aerts, J. et al. | 2015